Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19248981 | 0.88 | MEN1 (0.59) | MEN1KMT2ACYP1A2MEP1BACP3 | |
| SCHEMBL27827175 | 0.88 | MEN1 (0.59) | MEN1KMT2ACYP1A2MEP1BACP3 | |
| SCHEMBL1696017 | 0.88 | MEN1 (0.59) | MEN1KMT2ACYP1A2MEP1BACP3 | |
| SCHEMBL6243334 | 0.85 | ALDH1A1 (0.55) | MEN1KMT2ATSHRMEP1BACP3 | |
| SCHEMBL11350168 | 0.84 | CYP1A2 (0.56) | MEN1KMT2ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2485050 | 0.84 | SMN1; SMN2 (0.59) | MEN1KMT2AF2F10PRSS1 | |
| SCHEMBL16664378 | 0.84 | ALDH1A1 (0.50) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2485602 | 0.84 | ALDH1A1 (0.50) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2484892 | 0.83 | ALDH1A1 (0.49) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28387051 | 0.81 | LMNA (0.56) | MEN1KMT2AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| EP-2077999-B1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-12-16 | — | — | US | disclosed |
| EP-2077999-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Chroma Therapeutics Limited (GB) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | H1-2, HDAC1, H1-0 | MEN1 1608/4885KMT2A 92/4885CYP1A2 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.